Pneumococcal Vaccination in Older Persons: Where Are We Today?

Overview

Journal Pneumonia (Nathan)

Publisher Biomed Central

Date 2018 Jan 11

PMID 29318106

Citations 7

Authors

Paul Van Buynder

Robert Booy

Affiliations

Soon will be listed here.

Abstract

Disease due to , the pneumococcus, remains a major source of illness in older persons. Globally, it remains the most important pathogen in respiratory infection deaths. Conjugated pneumococcal vaccines are used extensively in national pediatric programs, whereas a polysaccharide vaccine is used in all age groups, but mainly in the elderly and for high-risk groups. Recent data from the Netherlands led to the licensing in many countries of conjugated pneumococcal vaccines for older persons. There are substantial differences in recommendations from various national immunization technical advisory groups, which owe at least as much to differing assessments of available studies as to differences in local epidemiology. This review examines those differences and proposes a way forward.

Citing Articles

The Two Faces of Bacterial Membrane Vesicles: Pathophysiological Roles and Therapeutic Opportunities.

Thapa H, Ebenberger S, Schild S Antibiotics (Basel). 2023; 12(6).

PMID: 37370364 PMC: 10295235. DOI: 10.3390/antibiotics12061045.

Multidimensional Frailty and Vaccinations in Older People: A Cross-Sectional Study.

Veronese N, Vassallo G, Armata M, Cilona L, Casalicchio S, Masnata R Vaccines (Basel). 2022; 10(4).

PMID: 35455304 PMC: 9028390. DOI: 10.3390/vaccines10040555.

B Cell Immunosenescence.

Frasca D, Diaz A, Romero M, Garcia D, Blomberg B Annu Rev Cell Dev Biol. 2020; 36:551-574.

PMID: 33021823 PMC: 8060858. DOI: 10.1146/annurev-cellbio-011620-034148.

The Contagion of Pneumonia in Older Persons: An Application of the Bass Diffusion Model.

Garcia L Gerontol Geriatr Med. 2020; 6:2333721420949308.

PMID: 32923521 PMC: 7448265. DOI: 10.1177/2333721420949308.

New MoDC-Targeting TNF Fusion Proteins Enhance Cyclic Di-GMP Vaccine Adjuvanticity in Middle-Aged and Aged Mice.

Gogoi H, Mansouri S, Katikaneni D, Jin L Front Immunol. 2020; 11:1674.

PMID: 32849581 PMC: 7427090. DOI: 10.3389/fimmu.2020.01674.

References

Musher D, Mediwala R, Phan H, Chen G, Baughn R . Nonspecificity of assaying for IgG antibody to pneumolysin in circulating immune complexes as a means to diagnose pneumococcal pneumonia. Clin Infect Dis. 2001; 32(4):534-8. DOI: 10.1086/318709. View

Vila-Corcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodriguez T . Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis. 2006; 43(7):860-8. DOI: 10.1086/507340. View

Furumoto A, Ohkusa Y, Chen M, Kawakami K, Masaki H, Sueyasu Y . Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine. 2008; 26(33):4284-9. DOI: 10.1016/j.vaccine.2008.05.037. View

Maruyama T, Taguchi O, Niederman M, Morser J, Kobayashi H, Kobayashi T . Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ. 2010; 340:c1004. PMC: 2834887. DOI: 10.1136/bmj.c1004. View

Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y . Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine. 2010; 28(43):7063-9. DOI: 10.1016/j.vaccine.2010.08.010. View

Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson L . Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine. 2012; 30(36):5437-44. DOI: 10.1016/j.vaccine.2012.05.076. View

Andrews N, Waight P, George R, Slack M, Miller E . Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012; 30(48):6802-8. DOI: 10.1016/j.vaccine.2012.09.019. View

Moberley S, Holden J, Tatham D, Andrews R . Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013; (1):CD000422. PMC: 7045867. DOI: 10.1002/14651858.CD000422.pub3. View

Griffin M, Zhu Y, Moore M, Whitney C, Grijalva C . U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013; 369(2):155-63. PMC: 4877190. DOI: 10.1056/NEJMoa1209165. View

10.

Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X . Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis. 2014; 58(7):909-17. DOI: 10.1093/cid/ciu002. View

11.

Harboe Z, Dalby T, Weinberger D, Benfield T, Molbak K, Slotved H . Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014; 59(8):1066-73. DOI: 10.1093/cid/ciu524. View

12.

Garcia Gabarrot G, Vega M, Perez Giffoni G, Hernandez S, Cardinal P, Felix V . Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country. PLoS One. 2014; 9(11):e112337. PMC: 4223029. DOI: 10.1371/journal.pone.0112337. View

13.

. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 385(9963):117-71. PMC: 4340604. DOI: 10.1016/S0140-6736(14)61682-2. View

14.

Russell K, Baker C, Hansen C, Poland G, Ryan M, Merrill M . Lack of effectiveness of the 23-valent polysaccharide pneumococcal vaccine in reducing all-cause pneumonias among healthy young military recruits: a randomized, double-blind, placebo-controlled trial. Vaccine. 2015; 33(9):1182-7. DOI: 10.1016/j.vaccine.2014.12.058. View

15.

Leventer-Roberts M, Feldman B, Brufman I, Cohen-Stavi C, Hoshen M, Balicer R . Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study. Clin Infect Dis. 2015; 60(10):1472-80. DOI: 10.1093/cid/civ096. View

16.

Bonten M, Huijts S, Bolkenbaas M, Webber C, Patterson S, Gault S . Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015; 372(12):1114-25. DOI: 10.1056/NEJMoa1408544. View

17.

Rodrigo C, Bewick T, Sheppard C, Greenwood S, McKeever T, Trotter C . Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J. 2015; 45(6):1632-41. DOI: 10.1183/09031936.00183614. View

18.

Pilishvili T, Bennett N . Pneumococcal disease prevention among adults: Strategies for the use of pneumococcal vaccines. Vaccine. 2015; 33 Suppl 4:D60-5. DOI: 10.1016/j.vaccine.2015.05.102. View

19.

van der Linden M, Falkenhorst G, Perniciaro S, Imohl M . Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. PLoS One. 2015; 10(7):e0131494. PMC: 4488910. DOI: 10.1371/journal.pone.0131494. View

20.

Kobayashi M, Bennett N, Gierke R, Almendares O, Moore M, Whitney C . Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015; 64(34):944-7. DOI: 10.15585/mmwr.mm6434a4. View